Cargando…
Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)
OBJECTIVE: To evaluate the effect of natalizumab on disability progression beyond 2 years of treatment in clinical practice. METHODS: Analyses included the 496 relapsing-remitting multiple sclerosis (RRMS) patients among 5122 patients in the Tysabri Observational Program (TOP) who had completed 4 co...
Autores principales: | Wiendl, Heinz, Butzkueven, Helmut, Kappos, Ludwig, Trojano, Maria, Pellegrini, Fabio, Paes, Dominic, Zhang, Annie, Belachew, Shibeshih |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714845/ https://www.ncbi.nlm.nih.gov/pubmed/26771747 http://dx.doi.org/10.1371/journal.pone.0144834 |
Ejemplares similares
-
Greater sensitivity to multiple sclerosis disability worsening and
progression events using a roving versus a fixed reference value in a
prospective cohort study
por: Kappos, Ludwig, et al.
Publicado: (2017) -
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2020) -
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014) -
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2021) -
Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)